Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233187 | 1.00 | CA12 (0.45) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5233199 | 1.00 | CA12 (0.45) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5235168 | 0.81 | GPR119 (0.37) | MAPK10 | |
| SCHEMBL5235171 | 0.81 | GPR119 (0.37) | MAPK10 | |
| SCHEMBL5235156 | 0.81 | GPR119 (0.37) | MAPK10 | |
| SCHEMBL5231490 | 0.81 | ALOX15 (0.36) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5231481 | 0.81 | ALOX15 (0.36) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5231498 | 0.81 | ALOX15 (0.36) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5234684 | 0.80 | PDK1 (0.33) | SMN1; SMN2ALDH1A1KMT2AMAPK1 | |
| SCHEMBL5236697 | 0.80 | PDK1 (0.33) | SMN1; SMN2ALDH1A1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | CA12 3227/4885CA1 1685/4885CA2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.